Apellis Pharmaceuticals Inc (APLS)
33.26
-1.37
(-3.96%)
USD |
NASDAQ |
Jan 08, 12:23
Apellis Pharmaceuticals Research and Development Expense (Annual): 354.39M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Biogen Inc | 2.462B |
| Biomarin Pharmaceutical Inc | 746.77M |
| Ionis Pharmaceuticals Inc | 899.62M |
| QuidelOrtho Corp | 246.80M |
| Moderna Inc | 4.845B |